News Article | May 5, 2017
ROCHESTER, NY, May 05, 2017-- Camillo Peracchia is a celebrated Marquis Who's Who biographee. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.Marquis Who's Who, the world's premier publisher of biographical profiles, is proud to name Dr. Peracchia a Lifetime Achiever. An accomplished listee, Dr. Peracchia celebrates many years' experience in his professional network, and has been noted for achievements, leadership qualities, and the credentials and successes he has accrued in his field.Dr. Peracchia serves as a professor emeritus of pharmacology and physiology with the University of Rochester Medical Center.In addition to his status as a Lifetime Achiever, Dr. Peracchia has earned a number of awards and accolades, including a Manuel D. Goldman Prize, an Adolph Medal for Excellence in Physiology from the University of Rochester Medical Center and five Teaching Commendation Awards. He has also earned grants from Rochester Eye and Human Parts, Inc., and the National Institutes of Health (Institute of General Medical Science). Furthermore, he has been featured in a number of Marquis Who's Who publications, including Who's Who in America, Who's Who in Medicine and Healthcare, Who's Who in Science and Engineering and Who's Who in the World.Dr. Peracchia is an elected member of the American Society for Cell Biology (1967-present) and the Biophysics Society (1980-present). He is an elected honorary member of the Societa di Medicina e Scienze Naturali di Parma, Universita di Parma, Italy (1994-present) and an elected member of the National Reviewers Reserve (NRR), NIH (June 1994-present). He was an elected member of the Cell Biology and Physiology Study Section (Subcommittee 1), NIH (October 1990-June 1994). He is the author of over 100 scientific papers, an invited speaker at over 40 International Congresses and invited speaker at over 100 seminars.For over five decades Dr. Peracchia's research has been focused on cell-to-cell communication via gap junction channels. In particular, Dr. Peracchia has studied the molecular mechanisms that regulate the chemical gating of gap junction channels. In the early 1980s Dr. Peracchia pioneered a theory that envisions a direct role of calmodulin (a calcium modulated protein) in the channel gating mechanism. Over the years this theory has been confirmed by numerous studies.Dr. Peracchia is the editor of three books:Peracchia, C. (Editor) 1991. Biophysics of Gap Junction Channels. CRC Press, Inc., Boca Raton, FLPeracchia, C. (Editor) 1994. "Handbook of Membrane Channels. Molecular and Cellular Physiology". Academic Press, Inc., San Diego, CAPeracchia, C. (Editor) 2000. "Gap Junctions - Molecular Basis of Cell Communication in Health and Disease". Academic Press, Inc., San Diego, CAHe is the author of the books:Peracchia, C. and Anaizi, N.H. "Lung Function in Health and Disease - Basic Concepts of Respiratory Physiology and Pathophysiology. Bentham Science Publishers, March 2014Peracchia, C. Gap Junction Structure and Chemical Regulation. Calmodulin Role in Cell-to-Cell Channel Gating. A personal journey. (book in preparation, projected date of publication: 2018).In recognition of outstanding contributions to his profession and the Marquis Who's Who community, Dr. Peracchia has been featured on the Marquis Who's Who Lifetime Achievers website. Please visit http://whoswholifetimeachievers.com/2017/03/13/camillo-peracchia/ to view this distinguished honor.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com
Pandey S.,Texas Tech University Health Sciences Center |
Simmons G.E.,University of Texas Southwestern Medical Center |
Malyarchuk S.,Molecular and Cellular Physiology |
Calhoun T.N.,Molecular and Cellular Physiology |
Pruitt K.,Texas Tech University Health Sciences Center
Genes and Cancer | Year: 2015
Methyl-CpG-binding protein-2 (MeCP2) regulates gene expression by recruiting SWI/SNF DNA helicase/ATPase (ATRX) and Histone Deacetylase-1 (HDAC1) to methylated gene regions and modulates heterochromatin association by interacting with Heterochromatin protein-1. As MeCP2 contributes to tumor suppressor gene silencing and its mutation causes Rett Syndrome, we investigated how novel posttranslational- modification contributes to its function. Herein we report that upon pharmacological inhibition of SIRT1 in RKO colon and MCF-7 breast cancer cells, endogenous MeCP2 is acetylated at sites critical for binding to DNA and transcriptional regulators. We created an acetylation mimetic mutation in MeCP2 and found it to possess decreased binding to ATRX and HDAC1. Conditions inducing MeCP2 acetylation do not alter its promoter occupancy at a subset of target genes analyzed, but do cause decreased binding to ATRX and HDAC1. We also report here that a specific inhibitor of SIRT1, IV, can be used to selectively decrease H3K27me3 repressive marks on a subset of repressed target gene promoters analyzed. Lastly, we show that RKO cells over-expressing MeCP2 mutant show reduced proliferation compared to those overexpressing MeCP2-wildtype. Our study demonstrates the importance of acetylated lysine residues and suggests their key role in regulating MeCP2 function and its ability to bind transcriptional regulators. © 2015, Impact Journals LLC. All rights reserved.
News Article | February 15, 2017
SAN DIEGO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Radicle, an accelerator fund dedicated to growing early stage agricultural and food technology startups into proven industry leaders, today announced the appointment of Jason Pyle, Paul Zorner, Sam Fiorello and Tom Urban to its team of experienced venture partners. Contributing decades of collective industry experience, Radicle’s newest partners add unique skills and operational expertise to its global Ag-focused network. Founded in 2016 by AgTech venture capital firm Finistere Ventures, Cloud Break Advisors and an alliance of top Ag industry leaders, including Bayer Crop Science, DuPont Pioneer and OurCrowd, Radicle offers a specialized platform to incubate high-quality AgTech companies that can solve global farming problems. The new Venture Partners join a global network of corporate, academic and industry leaders working with Radicle to drive the future of agriculture. “These four impressive individuals hold a wealth of industry knowledge and will play an instrumental role helping our portfolio companies meet their next value inflection point and earn their next round of funding,” said Kirk Haney, CEO and managing partner, Radicle. “Through the Radicle ecosystem, they will have visibility into the most innovative Ag and food tech startups around the globe. In close collaboration with Radicle’s extensive bench of Ag experts, researchers and proven entrepreneurs, these partners will help mentor and guide the next generation of AgTech innovators to ensure they reach their full potential.” Jason Pyle is an accomplished biotechnology executive with over 15 years of emerging technology experience. He founded and led successful biotechnology firms, including Triton Innovations, Fabric Media Inc., Sapphire Energy, Epoc Bioengineering Inc. and Pria Diagnostics. Pyle has received numerous awards for his contributions to biotechnology and his business leadership in the biological sciences, holds a number of pending and issued patents in the engineering and biological sciences, and has worked in diverse cross-discipline areas such as nanofabrication, optical engineering and structural biology. He earned both his M.D. and Ph.D. in Molecular and Cellular Physiology from the Stanford University School of Medicine. Paul Zorner, a Finistere Venture Partner and CEO of Locus Agricultural Solutions, also holds Board positions for other private companies operating to increase agricultural diversity and productivity, improve the nutritional content of food and create more productive agricultural systems. He has done substantial work in human and animal health, synthetic biology and the production of high-value chemistry from sustainable resources. He has held scientific, development, operations and senior administrative positions within start-up and Fortune 500 companies, and has been a founder of several agricultural and renewable energy-based companies focused on providing local food and economic security. He holds a degree from Lewis and Clark College and a Ph.D. in Botany and Plant Pathology from Colorado State University. Sam Fiorello, chief operating officer and senior vice president for administration and finance at The Donald Danforth Plant Science Center, has extensive experience managing financial, intellectual property and other operational functions. He is also president of Bio Research & Development Growth Park (BRDG Park) on the Danforth Center campus. Prior to joining the Danforth Center, he was chief of staff at Monsanto Company’s Office of the President, where he helped develop the business plan and initial pool of funding for the Danforth Plant Science Center. He holds a degree from the University of Wisconsin and a master’s in Public Administration from the University of Texas. Tom Urban has more than 20 years of experience in the agricultural industry, working for large Ag companies and as the CEO of a successful Ag startup. He also founded Agribusiness Advisors to help drive success for early-stage agricultural businesses. He is passionate about providing advice to companies facing common Ag market, product and financing challenges and helping investors properly identify and evaluate early-stage Ag technologies. Urban holds a degree from Middlebury College and an M.B.A. from the Harvard Graduate School of Business. “There is a huge opportunity for Ag and food tech pioneers to improve the food value chain, but entrepreneurs need to overcome tremendous obstacles to flourish in the Ag arena,” noted Tom Urban, Founder of Agribusiness Advisors. “I’m looking forward to working with the Radicle team to help entrepreneurs get access to funding, expertise and global network they need to build viable companies with the potential to reshape the future of food.” Focused on solving growers’ greatest challenges surrounding productivity, sustainability and quality in food and agriculture, Radicle invests in innovators in technology fields such as genomics and plant sciences, seed tech, biologicals for crop protection and regulation, digital Ag, and disruptive or novel farm systems. To learn more, visit radicle.vc. About Radicle Radicle is an accelerator fund backed by leading AgTech investors including Finistere Ventures, Bayer Crop Science, DuPont Pioneer and OurCrowd. Radicle carefully selects innovative Ag and food tech start-ups for investment, ensuring that powerful, disruptive technologies reach their full potential. We provide a fertile environment for visionaries in the Ag space, not just to grow but to flourish. Our proprietary platform is the only one of its kind in the agriculture industry, thus filling a huge void in the market by identifying the most innovative technologies and accelerating them with a range of value-creation initiatives. This starts with a significant investment of capital from Radicle, which is specifically designed for the unique needs of Ag and food tech start-ups. Equally as important as seed-stage capital is our network of venture partners who provide strategic advice and mentorship to our entrepreneurs. Additionally, Radicle provides operational services and access to strategic partnerships from our platform. These elements combine to make Radicle an unprecedented and robust platform for Ag and food tech start-ups.
PubMed | Lawrence Berkeley National Laboratory, Montana State University, Molecular and Cellular Physiology, Stanford University and 5 more.
Type: Journal Article | Journal: Proceedings of the National Academy of Sciences of the United States of America | Year: 2014
The emerging method of femtosecond crystallography (FX) may extend the diffraction resolution accessible from small radiation-sensitive crystals and provides a means to determine catalytically accurate structures of acutely radiation-sensitive metalloenzymes. Automated goniometer-based instrumentation developed for use at the Linac Coherent Light Source enabled efficient and flexible FX experiments to be performed on a variety of sample types. In the case of rod-shaped Cpl hydrogenase crystals, only five crystals and about 30 min of beam time were used to obtain the 125 still diffraction patterns used to produce a 1.6- resolution electron density map. For smaller crystals, high-density grids were used to increase sample throughput; 930 myoglobin crystals mounted at random orientation inside 32 grids were exposed, demonstrating the utility of this approach. Screening results from cryocooled crystals of 2-adrenoreceptor and an RNA polymerase II complex indicate the potential to extend the diffraction resolution obtainable from very radiation-sensitive samples beyond that possible with undulator-based synchrotron sources.